Biocept Highlights Scientific Poster Presented At 2023 ASCO Meeting
Portfolio Pulse from Benzinga Newsdesk
Biocept presented a scientific poster at the 2023 ASCO Meeting, highlighting a real-world retrospective study that showed increased sensitivity for CNSide relative to standard cerebral spinal fluid (CSF) cytology in detecting leptomeningeal metastases.
June 05, 2023 | 12:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biocept's presentation at the 2023 ASCO Meeting showcased the increased sensitivity of CNSide in detecting leptomeningeal metastases, potentially leading to increased adoption and sales.
The presentation at the ASCO Meeting highlights the increased sensitivity of Biocept's CNSide compared to standard CSF cytology in detecting leptomeningeal metastases. This positive data may lead to increased adoption of the product by healthcare providers, resulting in higher sales and a positive impact on Biocept's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100